Biovitrum selects Megapharm as distributor in Israel>
Biovitrum selects Megapharm as distributor in Israel
(Thomson Reuters ONE) - Stockholm - July 8, 2009. Biovitrum AB (publ) (STO: BVT) has enteredan exclusive distribution and marketing agreement with Megapharm Ltd.allowing Biovitrum's products Kineret® and Kepivance® to becommercialized in Israel.Megapharm has in the contract agreed to maintain a sales organizationto promote Kineret® and Kepivance® during 5 years. The products willbe filed for a market authorization to the Israeli authorities thisautumn and an approval is expected during 2010. "We are excited about the opportunity to work with Megapharm, aleading biotech marketing company in Israel. We are certain thatMegapharm will be able to effectively provide our innovative productsto patients who need them and thereby maximize the potential of theproducts," said Martin Nicklasson, CEO at Biovitrum.Miron Drucker, CEO and founder of Megapharm, said, "We are veryexcited to conclude this agreement with Biovitrum and to lend ourexpertise to successfully market and maximize the potential ofKineret and Kepivance in Israel. This will help to further reinforceour biologics portfolio and maintain our prominent position in therelevant therapeutic areas. We are proud to be associated withBiovitrum, and look forward to a long term and fruitfulrelationship".About Kineret® (anakinra)Information about Kineret® can be found at:http://www.kineretrx.com/Healthcare professionals should refer to and rely upon the PDR(Physician's Desk Reference) or the corresponding national labelingtexts, and not the information above.About Kepivance® (palifermin)Information about Kepivance® can be found at : http://www.kepivance.com/Healthcare professionals should refer to and rely upon the PDR(Physician's Desk Reference) or the corresponding national labelingtexts, and not the information aboveAbout BiovitrumBiovitrum is an international pharmaceutical company that marketsspecialist pharmaceuticals in several regions. Using its expertiseand experience Biovitrum takes scientific innovation to patients withsignificant unmet medical need. Research expertise and capabilitiesare focused on development and production of biotechnologytherapeutics within our prioritized areas of hemophilia,inflammation/autoimmune diseases, cancer supportive care andmalabsorption. The company has revenues of approximately SEK 1.2billion and around 400 employees. The company head office is locatedin Sweden and it is listed on the Stockholm OMX Nordic Exchange. Formore information please visit www.biovitrum.comAbout MegapharmMegapharm Ltd. is one of the leading private biotech, pharmaceuticaland medical nutrition marketing companies in Israel with a strongbiotech orientation, exclusively representing a number of majorAmerican and European pharmaceutical companies. Megapharm hasdemonstrated dynamic sales growth by developing a strong companypresence and expertise in select therapeutic areas, and diversifiedsegments of the healthcare business. The company also has arecognized and proven track record for obtaining reimbursement andinclusion of its products in all the health funds in Israel. For moreinformation see www.megapharm.co.ilFor more information please contact:BiovitrumMartin Nicklasson, CEOPhone: +46 8 697 2545Erik Kinnman, VP Investor RelationsCell phone: +46 73 422 15 40erik.kinnman(at)biovitrum.comMegapharmMiron Drucker, CEOPhone: +972 9 7604596admin(at)megapharm.co.ilBiovitrum AB (publ) may be required to disclose the informationprovided herein pursuant to the Swedish Securities Markets Act. Theinformation was provided for public release on July 8, 2009 at 8.30a.m. CET.http://hugin.info/134557/R/1327641/312827.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Mandatory notification of trade>
">
" alt="ÿaldag Off-take Termination Agreement and Bridging Facility Agreement
Signed>
">
Datum: 08.07.2009 - 02:30 Uhr
Sprache: Deutsch
News-ID 1002063
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
London
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 178 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biovitrum selects Megapharm as distributor in Israel>
"
steht unter der journalistisch-redaktionellen Verantwortung von
Biovitrum (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
